Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
Decision brief
Answer first · skim in under a minute
A recent Cleveland Clinic study confirms that tissue-derived tumor mutation burden (tTMB) is a more reliable predictor of immunotherapy response compared to blood-based TMB (bTMB). This finding serves as a cautionary note for physicians considering liquid biopsy results alone for treatment decisions.
Tumor Mutation Burden measured in tissue still outperforms blood-based TMB for immunotherapy selection when tests disagree, based on Cleveland Clinic ASCO 2026 data covering 221 paired patients and 80 treated with checkpoint inhibitors.
Contents12 sections
Key Takeaways
- 221 solid-tumor patients had paired tissue and blood TMB; 80 received checkpoint inhibitors.
- Blood TMB was a median 2.3× higher than matched tissue TMB.
- High tissue/low blood TMB: median time-to-treatment failure 21.3 months.
- High blood/low tissue TMB: about 7 months even after raising blood cutoffs.
What did the Cleveland Clinic ASCO 2026 study examine?
Investigators analyzed patients in the institutional genomics repository with at least one tissue TMB and one blood TMB result between July 2019 and July 2025.
Of 221 patients with solid tumors, 80 received immune checkpoint inhibitors and entered the outcomes analysis.
The abstract appears in the ASCO meeting library as JCO abstract 2580 (doi.org).
How concordant are tissue and blood Tumor Mutation Burden values?
Blood TMB ran consistently higher—a median of 2.3 times matched tissue values.
Despite the absolute gap, correlation remained strong (R-squared about 0.82 overall and 0.85 in the treated subgroup).
Correlation alone is not enough for treatment decisions when discordance changes outcomes.
What happens when tissue and blood TMB disagree?
Patients with high tissue TMB and low blood TMB had the best median time-to-treatment failure at 21.3 months.
Patients with high blood TMB and low tissue TMB did far worse, with a median near 7 months.
Raising the blood threshold from 10 to 16 mutations/Mb improved the low-tissue group only to 7 months—still behind high-tissue patients.
- Cohort: 221 paired TMB patients
- ICI subset: 80 patients
- Median bTMB/tTMB ratio: 2.3×
How does this relate to FDA's TMB-high pembrolizumab label?
FDA approved pembrolizumab for TMB-high solid tumors using a tissue-based threshold; see the FDA TMB-H approval summary.
That regulatory anchor still points clinicians toward tissue assays when both sample types exist.
Liquid biopsy remains useful when tissue is unavailable, but should not silently override a low tissue result.
What should pharma diagnostic strategies take from this?
Companion diagnostic plans for checkpoint inhibitors should keep tissue TMB as the decision standard.
Blood TMB can triage or monitor but needs tumor-specific thresholds before replacing tissue.
Larger tumor-stratified studies are still required before guidelines rewrite testing algorithms.
What remains unproven?
The ASCO analysis is single-center and mixed across solid tumors.
Optimal blood cutoffs by histology are not settled.
Until multi-vendor validation lands, treat blood-only high TMB as hypothesis-generating when tissue is low.
Why do blood assays inflate Tumor Mutation Burden counts?
Circulating tumor DNA assays can capture clonal hematopoiesis and assay noise that inflate mutation counts relative to a tissue biopsy.
That technical bias helps explain why blood TMB ran a median 2.3 times higher than matched tissue Tumor Mutation Burden values in the Cleveland Clinic series.
Without tumor-type-specific cutoffs, a universal blood threshold will misclassify patients at the margin of immunotherapy eligibility.
What should medical affairs teams tell physicians now?
When tissue Tumor Mutation Burden is available, use it for tumor-agnostic immunotherapy eligibility decisions ahead of blood-only results.
If only blood TMB exists, document the limitation and avoid overriding a prior low tissue result without new biopsy evidence.
Larger multi-vendor studies stratified by tumor type are still needed before guidelines rewrite testing algorithms.
Diagnostic partners should publish discordance rates alongside marketing claims for liquid TMB panels.
Until larger histology-specific datasets arrive, keep tissue Tumor Mutation Burden as the default gate for tumor-agnostic checkpoint therapy decisions.
Clinicians deciding immunotherapy from Tumor Mutation Burden should record whether the qualifying assay was tissue or blood and why that choice was made for each patient.
Related NovaPharma coverage
Frequently Asked Questions
Does tissue TMB outperform blood TMB for immunotherapy decisions?
A Cleveland Clinic real-world analysis presented at ASCO 2026 found tissue TMB remained the more reliable predictor of checkpoint-inhibitor benefit when tissue and blood results disagreed.
How much higher is blood TMB than tissue TMB?
In matched samples from 221 patients, blood TMB ran a median of 2.3 times higher than tissue TMB, even though the two measures still correlated (R-squared about 0.82 overall).
What outcomes were seen when tissue and blood TMB disagreed?
Patients with high tissue TMB but low blood TMB had median time-to-treatment failure of 21.3 months, versus about 7 months for high blood TMB with low tissue TMB even after raising the blood threshold.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
